A multidisciplinary training program in prostate cancer

前列腺癌多学科培训计划

• 批准号: 10647674
• 负责人: Neil A. Bhowmick
• 金额: $ 31.91万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10647674
• 关键词: Malignant neoplasm of prostate; Training Programs; multidisciplinary

Prostate cancer is the second leading cause of cancer related death in men in the United States, with approximately 29,000 deaths projected for 2018. It is initially responsive to androgen-ablation, but eventually progresses to a more advanced disease state known as metastatic castration-resistant prostate cancer. There are currently six FDA-approved therapies for mCRPC each of which extends survival by approximately 2-4 months. However, with nearly 165,000 men diagnosed yearly and over a million living with the disease in the US, managing quality of life and risk of progression of the disease are unmet concerns that need attention. The Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center treat the highest volume of cancer patient on the west coast. The translation of research discoveries contributing to more effective ways to diagnose, treat, and prevent many forms of cancer is a core mission of the SOCCI. The 14 faculty (primary and secondary) dedicated to training PhD, MD, and MD/PhD in prostate cancer 1) biology, 2) clinical trial, and 3) health services research contribute to the institutional commitment to high level of cancer patient care. As evidence, 88% of the trainees (Ph.D. and M.D.) that left the program in the past five years are doing research in academics or pharmaceutical industry. The translation of the bench science to clinical trials and development of experimental hypothesizes from clinical observations is derived from collaborations with clinician/surgeon-scientists. All trainees will participate in responsible conduct in research, grant writing and communication workshops, and biostatistics modules along with regular conferences and seminars. On average, 4.6 new training grant eligible (TGE) postdoctoral fellows are available yearly to the Prostate Cancer Training Program faculty; we are requesting funding support for one new postdoctoral trainee in years 1-2 and two new fellows in years 3-5 to develop leaders in collaborative prostate cancer research to promote better patient care. The population of southern California and interactions with underrepresented minority graduate programs throughout the country are part of the applicant pool. In the past five years, 25% of the TGE postdoctoral candidates that joined the program were underrepresented minority. This new T32 application plans for rigorous research training, personalized career development, and close mentorship to address the needs of young investigators and cancer patient care.

前列腺癌是美国男性癌症相关死亡的第二大原因， 预计 2018 年将有约 29,000 人死亡。它最初对雄激素消除有反应，但最终 进展为更晚期的疾病状态，称为转移性去势抵抗性前列腺癌。那里 目前 FDA 批准了六种治疗 mCRPC 的疗法，每种疗法均可将生存期延长约 2-4 几个月。然而，每年有近 165,000 名男性被诊断出患有这种疾病，超过 100 万人患有这种疾病。 在美国，管理生活质量和疾病进展风险是需要关注的未解决问题。这 Cedars-Sinai 医疗中心的 Samuel Oschin 综合癌症研究所 (SOCCI) 治疗最高 西海岸的癌症患者数量。研究发现的转化有助于提高效率 诊断、治疗和预防多种癌症的方法是 SOCCI 的核心使命。 14个教职人员 （小学和中学）致力于培养前列腺癌方面的博士、医学博士和医学博士/博士 1) 生物学，2) 临床 试验，以及 3) 卫生服务研究有助于机构对高水平癌症患者的承诺 关心。作为证据，过去五年中离开该项目的学员（博士和医学博士）中有 88% 正在做 学术或制药行业的研究。将实验室科学转化为临床试验 根据临床观察得出的实验假设源自与以下机构的合作 临床医生/外科医生科学家。所有学员都将参与负责任的研究、资助写作和 交流讲习班、生物统计模块以及定期会议和研讨会。平均而言， 4.6 每年有新的符合培训补助金资格 (TGE) 的博士后研究员参加前列腺癌培训 项目教师；我们请求为第 1-2 年的一名新博士后实习生和两名新博士后实习生提供资金支持 3-5 年的研究员培养前列腺癌合作研究的领导者，以促进更好的患者护理。 南加州的人口以及与代表性不足的少数族裔研究生项目的互动 全国各地都是申请人库的一部分。过去五年，25%的T​​GE博士后 加入该方案的候选人属于少数群体。这个新的T32应用程序计划严格 研究培训、个性化职业发展和密切指导，以满足年轻人的需求 研究人员和癌症患者护理。

项目成果

Nature versus nurture contribution to prostate cancer risk.

• DOI: 10.1038/s41585-022-00650-w
• 发表时间: 2022-11
• 期刊: Nature reviews. Urology

Plant-based diets to reduce prostate cancer risk and improve prostate cancer outcomes-ready for prime time?

以植物为基础的饮食可降低前列腺癌风险并改善前列腺癌结果——准备好迎接黄金时期了吗？

• DOI: 10.1038/s41391-022-00601-x
• 发表时间: 2023
• 期刊: Prostate cancer and prostatic diseases
• 影响因子: 4.8
• 作者: Friedrich,NadineA;Freedland,StephenJ;Csizmadi,Ilona
• 通讯作者: Csizmadi,Ilona

Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis.

• DOI: 10.21037/tau-23-114
• 发表时间: 2023-10-31
• 期刊: Translational andrology and urology
• 影响因子: 2